Charles Schwab Investment Management Inc. Buys 23,738 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Charles Schwab Investment Management Inc. raised its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 3.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 712,811 shares of the company’s stock after purchasing an additional 23,738 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.82% of IDEAYA Biosciences worth $18,319,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. R Squared Ltd bought a new position in IDEAYA Biosciences in the fourth quarter valued at approximately $35,000. KBC Group NV grew its stake in IDEAYA Biosciences by 29.1% in the third quarter. KBC Group NV now owns 2,274 shares of the company’s stock valued at $72,000 after purchasing an additional 513 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of IDEAYA Biosciences in the third quarter valued at approximately $83,000. Paloma Partners Management Co acquired a new stake in shares of IDEAYA Biosciences in the third quarter valued at approximately $213,000. Finally, Bellevue Group AG lifted its position in shares of IDEAYA Biosciences by 26.3% in the third quarter. Bellevue Group AG now owns 7,200 shares of the company’s stock valued at $228,000 after buying an additional 1,500 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors.

IDEAYA Biosciences Price Performance

Shares of NASDAQ IDYA opened at $18.21 on Thursday. The stock has a market capitalization of $1.59 billion, a PE ratio of -5.52 and a beta of 0.76. The business has a fifty day moving average price of $21.55 and a two-hundred day moving average price of $26.80. IDEAYA Biosciences, Inc. has a fifty-two week low of $16.95 and a fifty-two week high of $46.40.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The business had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $7.00 million. On average, equities analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on IDYA shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Stephens reaffirmed an “overweight” rating and issued a $50.00 price objective on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Wedbush reaffirmed an “outperform” rating and issued a $52.00 price objective on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $53.58.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.